233 related articles for article (PubMed ID: 29376946)
1. Virulence Factors as Targets for Anticryptococcal Therapy.
Azevedo RVDM; Rizzo J; Rodrigues ML
J Fungi (Basel); 2016 Nov; 2(4):. PubMed ID: 29376946
[TBL] [Abstract][Full Text] [Related]
2. Fenbendazole Controls
de Oliveira HC; Joffe LS; Simon KS; Castelli RF; Reis FCG; Bryan AM; Borges BS; Medeiros LCS; Bocca AL; Del Poeta M; Rodrigues ML
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253211
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcal therapies and drug targets: the old, the new and the promising.
Coelho C; Casadevall A
Cell Microbiol; 2016 Jun; 18(6):792-9. PubMed ID: 26990050
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyaldimines as potent in vitro anticryptococcal agents.
Magalhães TF; da Silva CM; de Fátima Â; da Silva DL; Modolo LV; Martins CV; Alves RB; Ruiz AL; Longato GB; de Carvalho JE; de Resende-Stoianoff MA
Lett Appl Microbiol; 2013 Aug; 57(2):137-43. PubMed ID: 23594040
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
6. Novel Antifungal Activity for the Lectin Scytovirin: Inhibition of
Jones TH; McClelland EE; McFeeters H; McFeeters RL
Front Microbiol; 2017; 8():755. PubMed ID: 28536555
[TBL] [Abstract][Full Text] [Related]
7. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
8. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
9. Chitosan Biosynthesis and Virulence in the Human Fungal Pathogen Cryptococcus gattii.
Lam WC; Upadhya R; Specht CA; Ragsdale AE; Hole CR; Levitz SM; Lodge JK
mSphere; 2019 Oct; 4(5):. PubMed ID: 31597720
[No Abstract] [Full Text] [Related]
10. Histopathological study of murine pulmonary cryptococcosis induced by Cryptococcus gattii and Cryptococcus neoformans.
Okubo Y; Wakayama M; Ohno H; Yamamoto S; Tochigi N; Tanabe K; Kaneko Y; Yamagoe S; Umeyama T; Shinozaki M; Nemoto T; Nakayama H; Sasai D; Ishiwatari T; Shimodaira K; Yamamoto Y; Kamei K; Miyazaki Y; Shibuya K
Jpn J Infect Dis; 2013; 66(3):216-21. PubMed ID: 23698482
[TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Laccase Expression to Immune Response against Cryptococcus gattii Infection.
Hansakon A; Ngamskulrungroj P; Angkasekwinai P
Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31871099
[TBL] [Abstract][Full Text] [Related]
14. Screening of Natural Lead Molecules Against Putative Molecular Targets of Drug-resistant Cryptococcus spp: An Insight from Computer-aided Molecular Design.
Manjunath M; Skariyachan S
Curr Top Med Chem; 2018; 18(31):2681-2701. PubMed ID: 30659541
[TBL] [Abstract][Full Text] [Related]
15. Essential gene discovery in the basidiomycete Cryptococcus neoformans for antifungal drug target prioritization.
Ianiri G; Idnurm A
mBio; 2015 Mar; 6(2):. PubMed ID: 25827419
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type VGI in Brazil: a case report and review of literature.
Nascimento E; Bonifácio da Silva ME; Martinez R; von Zeska Kress MR
Mycoses; 2014 Jul; 57(7):442-7. PubMed ID: 24612099
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Putative Anticryptococcal Properties of Crude and Clarified Extracts from Mollusks.
Gutierrez-Gongora D; Raouf-Alkadhimi F; Prosser RS; Geddes-McAlister J
J Vis Exp; 2022 Dec; (190):. PubMed ID: 36533849
[TBL] [Abstract][Full Text] [Related]
18. [Urease activity in Cryptococcus neoformans and Cryptococcus gattii].
Torres-Rodríguez JM; Alvarado-Ramírez E; Gutiérrez-Gallego R
Rev Iberoam Micol; 2008 Mar; 25(1):27-31. PubMed ID: 18338924
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcus neoformans variety gattii.
Sorrell TC
Med Mycol; 2001 Apr; 39(2):155-68. PubMed ID: 11346263
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
